Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis

Treatment patterns and survival outcomes for small-cell lung cancer patients – a Swedish single center cohort study

“…Patients receiving PDCT who have signs of relapse can be divided into refractory and sensitive groups. The definitions of platinum 'sensitive' and 'refractory' disease vary between previous studies; either with progression-free survival (PFS) of or <180 days from the start of 1st line treatment, or of or <90 days after the end of PDCT, respectively [3][4][5]. Patients without signs of relapse after 1st line therapy are not included in these definitions.…”

“…Hence, patients with 'sensitive relapse' (Sr) are recommended re-challenge with PDCT, while patients with 'refractory relapse' (Rr) are recommended a non-platinum based regimen as second line (2nd line). These recommendations though, are not based on results from randomized clinical trials [5]. Topotecan, in fact, is the only FDA-approved agent for 2nd line treatment in SCLC, based on the results of three phase III trials [6][7][8].…”

Small Cell Lung Cancer: Advances in Diagnosis and Management

“…Multiple other chemotherapy agents have shown activity comparable to topotecan in the second-line setting, including IP, [70][71][72] etoposide, 73 paclitaxel, 74,75 docetaxel, 76 gemcitabine, 77,78 vinca alkaloids (vinflunine and vinorelbine), 79,80 and temozolomide. 81,82 While many of these agents are used in clinic, none have proven to be superior to topotecan.…”

Is chemotherapy rechallenge feasible in advanced-stage non-small-cell lung cancer?

“…Pemetrexed rechallenge is indicated in malignant pleural mesothelioma when initial progressionfree survival exceeds 12 months [14]. In disseminated relapsing small-cell lung cancer, rechallenge with a platinum doublet plus etoposide is considered an option in platinum-sensitive disease [15]. In the same manner, carboplatin rechallenge is common practice in platinum-sensitive relapsing ovarian cancer [16].…”